ITRM20050290A1 - Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. - Google Patents

Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.

Info

Publication number
ITRM20050290A1
ITRM20050290A1 IT000290A ITRM20050290A ITRM20050290A1 IT RM20050290 A1 ITRM20050290 A1 IT RM20050290A1 IT 000290 A IT000290 A IT 000290A IT RM20050290 A ITRM20050290 A IT RM20050290A IT RM20050290 A1 ITRM20050290 A1 IT RM20050290A1
Authority
IT
Italy
Prior art keywords
ngf
analgesics
inhibit
molecules
bond
Prior art date
Application number
IT000290A
Other languages
English (en)
Inventor
Antonino Cattaneo
Sara Marinelli
Flaminia Pavone
Gabriele Ugolini
Original Assignee
Lay Line Genomics Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lay Line Genomics Spa filed Critical Lay Line Genomics Spa
Priority to IT000290A priority Critical patent/ITRM20050290A1/it
Priority to MX2007015487A priority patent/MX2007015487A/es
Priority to CN2006800288760A priority patent/CN101277718B/zh
Priority to NZ564071A priority patent/NZ564071A/en
Priority to US11/921,826 priority patent/US9688749B2/en
Priority to RU2007147625/15A priority patent/RU2427387C2/ru
Priority to AU2006256387A priority patent/AU2006256387B2/en
Priority to EP11188102A priority patent/EP2484380A1/en
Priority to PCT/IT2006/000427 priority patent/WO2006131952A1/en
Priority to EP06756317A priority patent/EP1893234A2/en
Priority to KR1020087000315A priority patent/KR101486085B1/ko
Priority to CA002610596A priority patent/CA2610596A1/en
Priority to JP2008515383A priority patent/JP5133879B2/ja
Priority to CA2611433A priority patent/CA2611433C/en
Priority to PCT/IT2006/000426 priority patent/WO2006131951A2/en
Priority to DK06756318.9T priority patent/DK1890726T3/en
Priority to HK09101888.4A priority patent/HK1121403B/xx
Priority to EP06756318.9A priority patent/EP1890726B1/en
Priority to JP2008515384A priority patent/JP5730464B2/ja
Priority to US11/921,398 priority patent/US8691221B2/en
Publication of ITRM20050290A1 publication Critical patent/ITRM20050290A1/it
Priority to NO20080084A priority patent/NO20080084L/no
Priority to JP2012106277A priority patent/JP2012158604A/ja
Priority to JP2013037304A priority patent/JP2013151509A/ja
Priority to JP2014163809A priority patent/JP2014218513A/ja

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IT000290A 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato. ITRM20050290A1 (it)

Priority Applications (24)

Application Number Priority Date Filing Date Title
IT000290A ITRM20050290A1 (it) 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
JP2008515383A JP5133879B2 (ja) 2005-06-07 2006-06-07 ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子
CA002610596A CA2610596A1 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect
NZ564071A NZ564071A (en) 2005-06-07 2006-06-07 Use of an anti-NGF IgG4 isotype antibody for treating and/or preventing chronic pain
US11/921,826 US9688749B2 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
RU2007147625/15A RU2427387C2 (ru) 2005-06-07 2006-06-07 МОЛЕКУЛЫ, СПОСОБНЫЕ ИНГИБИРОВАТЬ СВЯЗЫВАНИЕ МЕЖДУ NGF И РЕЦЕПТОРОМ TrkA, В КАЧЕСТВЕ АНАЛЬГЕТИКОВ С ПРОЛОНГИРОВАННЫМ ЭФФЕКТОМ
AU2006256387A AU2006256387B2 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
CN2006800288760A CN101277718B (zh) 2005-06-07 2006-06-07 作为长效止痛剂的能抑制NGF与TrkA受体的结合的分子
PCT/IT2006/000427 WO2006131952A1 (en) 2005-06-07 2006-06-07 Novel analgesic treatment with prolonged effect
EP06756317A EP1893234A2 (en) 2005-06-07 2006-06-07 MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
KR1020087000315A KR101486085B1 (ko) 2005-06-07 2006-06-07 연장된 효과를 가지는 진통제로서 ＮＧＦ와 ＴｒｋＡ리셉터 사이의 결합을 억제할 수 있는 분자
MX2007015487A MX2007015487A (es) 2005-06-07 2006-06-07 Moleculas que son capaces de inhibir la union entre el factor de crecimiento de nervios y el receptor trka como analgesicos con efecto prolongado.
EP11188102A EP2484380A1 (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between NGF and the TrkA receptor as analgesics with prolonged effect
EP06756318.9A EP1890726B1 (en) 2005-06-07 2006-06-07 Novel analgesic treatment with prolonged effect
PCT/IT2006/000426 WO2006131951A2 (en) 2005-06-07 2006-06-07 MOLECULES THAT ARE ABLE TO INHIBIT THE BINDING BETWEEN NGF AND THE TrkA RECEPTOR AS ANALGESICS WITH PROLONGED EFFECT
DK06756318.9T DK1890726T3 (en) 2005-06-07 2006-06-07 New analgesic treatment with extended effect
HK09101888.4A HK1121403B (en) 2005-06-07 2006-06-07 Molecules that are able to inhibit the binding between ngf and the trka receptor as analgesics with prolonged effect
CA2611433A CA2611433C (en) 2005-06-07 2006-06-07 Novel analgesic treatment with prolonged effect using an anti-trka antibody
JP2008515384A JP5730464B2 (ja) 2005-06-07 2006-06-07 延長効果をもつ新規鎮痛治療
US11/921,398 US8691221B2 (en) 2005-06-07 2006-06-07 Analgesic treatment with prolonged effect
NO20080084A NO20080084L (no) 2005-06-07 2008-01-07 Molekyler som er i stand til a hemme bindingen mellom NGF og TrkA-reseptoren som analgetika med forlenget effekt
JP2012106277A JP2012158604A (ja) 2005-06-07 2012-05-07 ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子
JP2013037304A JP2013151509A (ja) 2005-06-07 2013-02-27 延長効果をもつ新規鎮痛治療
JP2014163809A JP2014218513A (ja) 2005-06-07 2014-08-11 ＮＧＦとＴｒｋＡレセプターとの結合を阻害することができる、長期化作用を有する鎮痛剤としての分子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000290A ITRM20050290A1 (it) 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.

Publications (1)

Publication Number Publication Date
ITRM20050290A1 true ITRM20050290A1 (it) 2006-12-08

Family

ID=37056613

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000290A ITRM20050290A1 (it) 2005-06-07 2005-06-07 Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.

Country Status (14)

Country Link
US (2) US9688749B2 (it)
EP (3) EP1893234A2 (it)
JP (5) JP5133879B2 (it)
KR (1) KR101486085B1 (it)
CN (1) CN101277718B (it)
AU (1) AU2006256387B2 (it)
CA (2) CA2611433C (it)
DK (1) DK1890726T3 (it)
IT (1) ITRM20050290A1 (it)
MX (1) MX2007015487A (it)
NO (1) NO20080084L (it)
NZ (1) NZ564071A (it)
RU (1) RU2427387C2 (it)
WO (2) WO2006131952A1 (it)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
ME02239B (me) 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR20130087632A (ko) 2007-12-17 2013-08-06 화이자 리미티드 간질성 방광염의 치료
WO2009098238A1 (en) * 2008-02-04 2009-08-13 Bioxell Spa Anti-trka antibodies and derivatives thereof
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
RU2010153580A (ru) 2008-06-03 2012-07-20 Эбботт Лэборетриз (Us) Иммуноглобулины с двумя вариабельными доменами и их применение
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
CN102149825B (zh) 2008-07-08 2015-07-22 Abbvie公司 前列腺素e2双重可变结构域免疫球蛋白及其用途
WO2010032220A1 (en) 2008-09-19 2010-03-25 Pfizer Inc. Stable liquid antibody formulation
WO2010033941A1 (en) 2008-09-22 2010-03-25 Array Biopharma Inc. Substituted imidazo[1,2b]pyridazine compounds as trk kinase inhibitors
SI2350071T1 (sl) 2008-10-22 2014-05-30 Array Biopharma, Inc. Substituirane pirazolo(1,5-a)pirimidinske spojine kot Trk kinazni inhibitorji
NZ593937A (en) 2008-12-08 2014-05-30 Vm Pharma Llc Compositions of protein receptor tyrosine kinase inhibitors
DK2398498T3 (en) 2009-02-17 2019-01-07 Ucb Biopharma Sprl ANTIBODY MOLECULES WITH SPECIFICITY FOR HUMAN OX40
EP2448970B1 (en) 2009-05-04 2014-07-09 Abbott Research B.V. Antibodies against nerve growth factor (ngf) with enhanced in vivo stability
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
CN102612524A (zh) * 2009-09-01 2012-07-25 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
WO2011047262A2 (en) * 2009-10-15 2011-04-21 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011116090A1 (en) * 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions
BR112012029405B1 (pt) 2010-05-20 2021-01-05 Array Biopharma Inc. compostos macrocíclicos como inibidores de trk quinase, composição farmacêutica, uso de um composto de fórmula i ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação de um composto
UY33492A (es) * 2010-07-09 2012-01-31 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
KR20130100118A (ko) 2010-08-03 2013-09-09 아비에 인코포레이티드 이원 가변 도메인 면역글로불린 및 이의 용도
ES2910305T3 (es) 2010-08-19 2022-05-12 Zoetis Belgium S A Anticuerpos anti-NGF y su uso
RU2013113225A (ru) 2010-08-26 2014-10-10 Эббви Инк. Иммуноглобулины с двумя вариабельными доменами и их применение
EP2646468B1 (en) 2010-12-01 2018-07-25 AlderBio Holdings LLC Anti-ngf compositions and use thereof
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
CA2835094C (en) * 2011-05-06 2020-12-22 David Gearing Anti-nerve growth factor antibodies and methods of preparing and using the same
CN103764677A (zh) * 2011-05-06 2014-04-30 Nvip私人有限公司 抗神经生长因子抗体及其制备和使用方法
SI3498732T1 (sl) 2011-05-06 2022-04-29 Zoetis Services Llc Protitelesa proti živčnemu rastnemu faktorju ter postopki za pripravo in uporabo le-teh
GB201114858D0 (en) 2011-08-29 2011-10-12 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of using the same
WO2012153122A1 (en) 2011-05-06 2012-11-15 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
GB2528401A (en) * 2011-05-06 2016-01-20 Nvip Pty Ltd Anti-nerve growth factor antibodies and methods of preparing and using the same
CN108359008B (zh) 2011-05-20 2022-03-29 H.伦德贝克公司 抗cgrp或抗cgrp-r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
EA034747B1 (ru) 2011-05-20 2020-03-17 Олдербайо Холдингз Ллк Способ предотвращения или ингибирования светобоязни или отвращения к свету с использованием антител против cgrp
EA201891284A1 (ru) 2011-05-20 2018-11-30 Олдербайо Холдингз Ллк Композиции антител против cgrp и их применение
EP2731439A4 (en) 2011-07-12 2014-12-03 Merck Sharp & Dohme TRKA KINASE INHIBITORS, COMPOSITIONS AND METHOD THEREFOR
US8926978B2 (en) 2011-10-25 2015-01-06 Anaptysbio, Inc. Antibodies directed against nerve growth factor (NGF)
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
CN104159920A (zh) 2011-12-30 2014-11-19 艾伯维公司 针对il-13和/或il-17的双重可变结构域免疫球蛋白
CA2856451A1 (en) * 2012-01-05 2013-07-11 Beech Tree Labs, Inc. Method of treating pain by administration of nerve growth factor
US9181261B2 (en) 2012-05-22 2015-11-10 Merck Sharp & Dohme Corp. TrkA kinase inhibitors, compositions and methods thereof
CN104364264B (zh) 2012-06-06 2018-07-24 硕腾服务有限责任公司 犬源化抗ngf抗体和其方法
AU2013273115B2 (en) * 2012-06-08 2018-03-01 Ichnos Sciences SA Humanized anti-TrkA antibodies with amino acid substitutions
EP2674439B1 (en) 2012-06-13 2017-02-01 Rottapharm Biotech S.r.l. Anti-TrkA antibodies, derivatives and uses thereof
WO2014071074A2 (en) 2012-11-01 2014-05-08 Abbvie Inc. Anti-vegf/dll4 dual variable domain immunoglobulins and uses thereof
TW201512219A (zh) 2013-03-15 2015-04-01 Abbvie Inc 針對ＩＬ－１β及／或ＩＬ－１７之雙特異性結合蛋白
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
WO2015039334A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
WO2015039333A1 (en) 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
PL3102555T3 (pl) 2014-02-05 2021-12-20 VM Oncology LLC Kompozycje związków i ich zastosowania
WO2015143653A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143652A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
WO2015143654A1 (en) 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
AU2015346046B2 (en) 2014-11-16 2020-06-25 Array Biopharma, Inc. Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate
MA41097A (fr) * 2014-12-05 2017-10-10 Glenmark Pharmaceuticals Sa Anticorps anti-trka à propriétés inhibitrices améliorées et dérivés desdits anticorps destinés à être utilisés pour traiter les douleurs osseuses
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AU2016210544B2 (en) 2015-01-23 2020-12-10 Gvk Biosciences Private Limited Inhibitors of TrkA kinase
WO2016161572A1 (en) 2015-04-08 2016-10-13 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3303631A1 (en) 2015-06-01 2018-04-11 Loxo Oncology Inc. Methods of diagnosing and treating cancer
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3322706B1 (en) 2015-07-16 2020-11-11 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
SG11201803438XA (en) 2015-10-26 2018-05-30 Univ Colorado Regents Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
TN2018000338A1 (en) 2016-04-04 2020-01-16 Loxo Oncology Inc Methods of treating pediatric cancers
MX386416B (es) 2016-04-04 2025-03-18 Loxo Oncology Inc Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida.
FI3800189T3 (fi) 2016-05-18 2023-07-31 Loxo Oncology Inc (s)-n-(5-((r)-2-(2,5-difluorifenyyli)pyrrolidin-1-yyli)pyratsolo[1,5-a]pyrimidin-3-yyli)-3-hydroksipyrrolidiini-1-karboksamidin valmistaminen
JOP20190077A1 (ar) 2016-10-10 2019-04-09 Array Biopharma Inc مركبات بيرازولو [1، 5-a]بيريدين بها استبدال كمثبطات كيناز ret
TWI704148B (zh) 2016-10-10 2020-09-11 美商亞雷生物製藥股份有限公司 作為ｒｅｔ激酶抑制劑之經取代吡唑并[1,5-a]吡啶化合物
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018136663A1 (en) 2017-01-18 2018-07-26 Array Biopharma, Inc. Ret inhibitors
CN110267960B (zh) 2017-01-18 2022-04-26 阿雷生物药品公司 作为RET激酶抑制剂的取代的吡唑并[1,5-a]吡嗪化合物
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
US20190247398A1 (en) 2017-10-26 2019-08-15 Array Biopharma Inc. Formulations of a macrocyclic trk kinase inhibitor
TW201932464A (zh) 2018-01-18 2019-08-16 美商亞雷生物製藥股份有限公司 作為ret激酶抑制劑之經取代吡唑基[4,3-c]吡啶化合物
EP3740490A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrazolo[3,4-d]pyrimidine compounds as ret kinase inhibitors
EP3740491A1 (en) 2018-01-18 2020-11-25 Array Biopharma, Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
MX2020009526A (es) 2018-03-12 2020-10-28 Zoetis Services Llc Anticuerpos anti-ngf y metodos de estos.
US20210023086A1 (en) 2018-03-29 2021-01-28 Loxo Oncology, Inc. Treatment of trk-associated cancers
US12109193B2 (en) 2018-07-31 2024-10-08 Loxo Oncology Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide
WO2020055672A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
JP2022515198A (ja) 2018-12-19 2022-02-17 アレイ バイオファーマ インコーポレイテッド ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物
WO2020131674A1 (en) 2018-12-19 2020-06-25 Array Biopharma Inc. 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer
PE20211707A1 (es) 2019-01-08 2021-09-01 H Lundbeck As Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anticgrp
EP3976657A4 (en) * 2019-05-30 2023-07-05 Sunshine Lake Pharma Co., Ltd. ANTI-TRKA ANTIBODIES AND USES THEREOF
BR102020007149A8 (pt) 2020-04-06 2023-09-26 H Lundbeck As Usos de um anticorpo anti-cgrp ou anti-cgrp-r ou um fragmento dos mesmos para melhorar o sintoma mais incômodo (mbs) e a impressão global de mudança (pgic) associados com enxaqueca
AU2020204105B2 (en) * 2020-06-19 2023-06-08 Dartsbio Pharmaceuticals Ltd. Anti-human ngf antibodies and methods using same
US11655292B2 (en) 2020-06-23 2023-05-23 Ampsource Biopharma Shanghai Inc. Anti-human NGF antibodies and methods using same
EP4308101A1 (en) * 2021-04-21 2024-01-24 Redyneuheart S.r.l. N-acetyl cysteine for neuraxial use as a trka tyrosine kinase receptor inhibitor for the treatment of acute and chronic pain
WO2023034880A2 (en) 2021-08-31 2023-03-09 Scout Bio, Inc. Antigen-binding molecules and uses thereof
WO2023125477A1 (en) 2021-12-28 2023-07-06 4B Technologies (Beijing) Co., Limited TrkA ANTIBODY AND APPLICATION THEREOF
EP4316481A1 (en) 2022-08-01 2024-02-07 Edmond Pharma S.R.L. Erdosteine, salts, enantiomers or metabolites thereof for use in the treatment of acute and chronic pain states
WO2025079006A1 (en) 2023-10-13 2025-04-17 Cephalon Llc Anti-trka antibodies and uses thereof

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4230691A (en) * 1978-05-23 1980-10-28 The Massachusetts General Hospital Nerve growth factor antibody and process
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SE465573B (sv) * 1989-03-14 1991-09-30 Lope Medicine Ab Nervtillvaextfaktorpeptider, motsvarande antikroppar och foerfarande foer bestaemning av nativ nervtillvaextfaktor
US5147294A (en) * 1990-10-01 1992-09-15 Trustees Of Boston University Therapeutic method for reducing chronic pain in a living subject
AU9059991A (en) 1990-11-13 1992-06-11 Children's Medical Center Corporation Controlling beta-amyloid related neuronal degeneration by antagonizing NGF-effected neuronal activity
EP0559834A1 (en) 1990-11-30 1993-09-15 Abbott Laboratories Immunoassay and monoclonal antibodies useful for detecting truncated nerve growth factor receptor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
EP0578515A3 (en) 1992-05-26 1995-05-10 Bristol Myers Squibb Co Humanized monoclonal antibodies.
US5639641A (en) * 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
GB9402331D0 (en) * 1994-02-07 1994-03-30 Univ Mcgill Nerve growth factor structural analogs and their uses
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5747060A (en) * 1996-03-26 1998-05-05 Euro-Celtique, S.A. Prolonged local anesthesia with colchicine
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
IT1306704B1 (it) 1999-05-26 2001-10-02 Sirs Societa Italiana Per La R Anticorpi monoclonali e suoi derivati sintetici o biotecnologici ingrado di agire come molecole antagoniste per il ngf.
DK1255824T3 (da) 1999-08-06 2010-07-19 S I S S A Scuola Internaz Supe Transgene mus til undersøgelse af neurodegenerative syndromer
DK1265605T3 (da) * 2000-01-18 2007-02-12 Univ Mcgill Farmaceutiske sammensætninger omfattende peptidmimetisk, cyklisk beta-drejningsforbindelse
US6548062B2 (en) * 2000-02-29 2003-04-15 Cephalon, Inc. Method of treating cancer with anti-neurotrophin agents
JP2003527861A (ja) 2000-03-16 2003-09-24 ジェネンテック・インコーポレーテッド 増強した抗血液凝固能を持つ抗組織因子抗体
FR2807660A1 (fr) * 2000-04-13 2001-10-19 Warner Lambert Co Utilisation d'antagonistes du ngf pour la prevention ou le traitement de douleurs viscerales chroniques
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US7507799B2 (en) * 2001-05-25 2009-03-24 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
CN101653604A (zh) * 2001-05-30 2010-02-24 基因技术股份有限公司 抗ngf抗体用于治疗各种疾病
SE0102067D0 (sv) 2001-06-11 2001-06-11 A & Science Invest Ab Prevention of neovascularization of intervertebral discs and/or of tissues with local inflammation
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
JP3729841B2 (ja) * 2001-10-15 2005-12-21 麒麟麦酒株式会社 抗ｈｌａ−ｄｒ抗体の利用
US6919426B2 (en) * 2002-09-19 2005-07-19 Amgen Inc. Peptides and related molecules that modulate nerve growth factor activity
AU2003284010A1 (en) 2002-10-04 2004-05-04 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DK1556083T3 (da) * 2002-10-08 2011-04-04 Rinat Neuroscience Corp Fremgangsmåde til behandling af post-operative smerter ved indgivelse af en antistof mod nervevækstfaktor og sammensætning indeholdende samme
WO2005000194A2 (en) 2002-10-08 2005-01-06 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
WO2004056385A2 (en) 2002-12-20 2004-07-08 Neuronicon Aps Modulation of activity of neurotrophins
US7569364B2 (en) * 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
KR101410692B1 (ko) * 2002-12-24 2014-06-24 리나트 뉴로사이언스 코프. 항-ｎｇｆ 항체 및 그것을 이용하는 방법
US20040131515A1 (en) * 2003-01-03 2004-07-08 Alexanian Ara J. Material heat treatment system and method statement regarding federally sponsored research or development
WO2004065560A2 (en) 2003-01-18 2004-08-05 Rinat Neuroscience Corp. Methods of screening for modulators of nerve growth factor
KR20050111598A (ko) 2003-02-19 2005-11-25 리나트 뉴로사이언스 코퍼레이션 신경 성장 인자 길항제 및 ｎｓａｉｄ를 투여함으로써통증을 치료하는 방법 및 그것을 함유하는 조성물
BRPI0412567B1 (pt) * 2003-07-15 2017-03-21 Amgen Inc anticorpo isolado, ou fragmento de imunoglobulina imunologicamente funcional ou ligante de antígeno do mesmo, composição farmacêutica, molécula de ácido nucleico, medicamento para tratar um distúrbio doloroso ou uma condição associada com a expressão aumentada de ngf ou a sensibilidade aumentada ao ngf, e, uso de uma quantidade farmaceuticamente efetiva de anticorpo ou fragmento de imunoglobulina imunologicamente funcional ou ligante de antígeno do mesmo
WO2005044293A2 (en) 2003-11-07 2005-05-19 Lay Line Genomics S.P.A. Compositions able to prevent neurodegenerative processes and methods of assaying the same
ITRM20030601A1 (it) 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
US7522822B2 (en) * 2004-01-06 2009-04-21 Robert Trujillo Halogen lamp assembly with integrated heat sink
KR101637908B1 (ko) 2004-04-07 2016-07-11 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
ITRM20040212A1 (it) 2004-04-30 2004-07-30 Lay Line Genomics Spa Animale transgenico non umano come modello per malattie neurodegenerative e per la loro diagnosi precoce.
ME00226B (me) * 2004-07-15 2011-02-10 Medarex Llc Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
KR101298383B1 (ko) * 2005-01-24 2013-08-20 엘란 파마 인터내셔널 리미티드 Ｎｇｆ에 대한 특이적 결합 멤버
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
ITRM20050332A1 (it) 2005-06-24 2006-12-25 Lay Line Genomics Spa Uso di molecole in grado di bloccare l'attivita' di trka per potenziare gli effetti di analgesici oppiacei sul dolore.
CA2790018C (en) 2006-12-21 2015-02-03 Amgen Inc. Formulations
EP4119579A1 (en) 2007-05-31 2023-01-18 Genmab A/S Stable igg4 antibodies
ME02239B (me) * 2007-08-10 2015-04-30 Regeneron Pharma Humana antitela visokog afiniteta prema humanom nervnom faktoru rasta
US8309088B2 (en) * 2007-08-10 2012-11-13 Regeneron Pharmaceuticals, Inc. Method of treating osteoarthritis with an antibody to NGF
KR20130087632A (ko) * 2007-12-17 2013-08-06 화이자 리미티드 간질성 방광염의 치료
WO2009098238A1 (en) 2008-02-04 2009-08-13 Bioxell Spa Anti-trka antibodies and derivatives thereof
CA2782712A1 (en) 2010-02-03 2011-08-11 Morinaga Milk Industry Co., Ltd. Method for manufacturing aloe powder
WO2011116090A1 (en) 2010-03-17 2011-09-22 Abbott Research B.V. Anti-nerve growth factor (ngf) antibody compositions

Also Published As

Publication number Publication date
EP1893234A2 (en) 2008-03-05
WO2006131951A3 (en) 2007-01-25
US8691221B2 (en) 2014-04-08
US20090208490A1 (en) 2009-08-20
JP2008542440A (ja) 2008-11-27
MX2007015487A (es) 2008-04-09
JP2008542439A (ja) 2008-11-27
JP5133879B2 (ja) 2013-01-30
RU2007147625A (ru) 2009-06-27
AU2006256387B2 (en) 2011-12-15
KR20080026593A (ko) 2008-03-25
RU2427387C2 (ru) 2011-08-27
JP2012158604A (ja) 2012-08-23
JP5730464B2 (ja) 2015-06-10
JP2013151509A (ja) 2013-08-08
KR101486085B1 (ko) 2015-01-28
WO2006131952A1 (en) 2006-12-14
JP2014218513A (ja) 2014-11-20
DK1890726T3 (en) 2015-02-16
AU2006256387A1 (en) 2006-12-14
CA2611433C (en) 2016-11-08
CA2611433A1 (en) 2006-12-14
WO2006131951A2 (en) 2006-12-14
US20100291083A1 (en) 2010-11-18
CN101277718B (zh) 2011-12-21
CN101277718A (zh) 2008-10-01
EP1890726B1 (en) 2014-11-19
EP2484380A1 (en) 2012-08-08
CA2610596A1 (en) 2006-12-14
HK1121403A1 (en) 2009-04-24
WO2006131952A8 (en) 2008-01-10
NO20080084L (no) 2008-03-07
EP1890726A1 (en) 2008-02-27
NZ564071A (en) 2011-07-29
US9688749B2 (en) 2017-06-27

Similar Documents

Publication Publication Date Title
ITRM20050290A1 (it) Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
BRPI0818144A2 (pt) Produção de termolisin e variantes deste, e uso em detergentes líquidos
PT1943264E (pt) Análogos de oligonucleosídeos incorporando neles 5-azacitosina
CR10847A (es) Compuesto heteromonociclico y uso del mismo
MA28989B1 (fr) MOLECULES Fc MODIFIEES
EP1865042A4 (en) ANTIFREEZE
FI20061034A0 (fi) Kaksiportainen ahtopuristusjärjestelmä
DE602006016400D1 (de) Damit
EP1889424A4 (en) MESSAGE TRANSMISSION IN PAGE MODE
ITMI20050119A1 (it) Struttura di pannello e relativo procedimento di realizzazione
ITPD20050014U1 (it) Pompa diamagnetica
FI20041503L (fi) Järjestely oskillointisylinterin yhteydessä
ITVR20050001U1 (it) Struttura di seggiolone
SE0502244L (sv) Blandnings- och pumpsystem
FIU20050132U0 (fi) Järjestely rakennenurkassa
ITMI20050667A1 (it) Vernice antivegetativa e suo uso
ITMI20050668A1 (it) Composizione verniciante procedimento per prepararla e suo uso
UY3545Q (es) Configuración aplicada en licuadora
ITFR20050004U1 (it) Traliccio "conte" muniti di due piattinecon tondino distanziatore
ITBO20050048U1 (it) Struttura di stipetto ripiegabile
FI6739U1 (fi) Repputeltta
ES1061725Y (es) Panel utilizado en la fabricacion de mobiliario
ITPD20050001U1 (it) Struttura di scrittoio
PT10032T (pt) Cinzeiro de praia
FI20051103A0 (fi) Sandwich-tyyppinen rakenne